Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)

NCT04042740 PHASE2 COMPLETED Results posted

The purpose of this study was to assess the efficacy of a fixed dose combination (FDC) of glecaprevir/pibrentasvir (G/P) given for 4 weeks for treatment of acute hepatitis C (HCV), with or without HIV-1 coinfection.

Details

Lead sponsor	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase	PHASE2
Status	COMPLETED
Enrolment	45
Start date	Wed Nov 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Hepatitis C Infection
• HIV Infection

Interventions

• Glecaprevir/Pibrentasvir (G/P)

Countries

United States, Brazil